Anna Lübking

820 total citations
14 papers, 236 citations indexed

About

Anna Lübking is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Anna Lübking has authored 14 papers receiving a total of 236 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Genetics and 6 papers in Rheumatology. Recurrent topics in Anna Lübking's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Eosinophilic Disorders and Syndromes (6 papers). Anna Lübking is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Eosinophilic Disorders and Syndromes (6 papers). Anna Lübking collaborates with scholars based in Sweden, Norway and Finland. Anna Lübking's co-authors include Sten Eirik W. Jacobsen, Charlotta Böiers, Shabnam Kharazi, Ewa Sitnicka, Christina T. Jensen, Martin Höglund, Leif Stenke, Johan Richter, Berit Markevärn and Ulla Olsson‐Strömberg and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Anna Lübking

14 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Lübking Sweden	9	156	109	66	65	55	14	236
Shinichiro Machida Japan	8	151 1.0×	60 0.6×	30 0.5×	53 0.8×	74 1.3×	39	258
Peter Rohoň Czechia	9	208 1.3×	155 1.4×	71 1.1×	67 1.0×	66 1.2×	33	283
Sabine Hertle Switzerland	5	139 0.9×	100 0.9×	49 0.7×	20 0.3×	45 0.8×	8	189
K Miyamura Japan	9	328 2.1×	74 0.7×	40 0.6×	70 1.1×	60 1.1×	15	366
H-J Kolb Germany	8	278 1.8×	61 0.6×	27 0.4×	54 0.8×	75 1.4×	9	317
Adriano Salaroli Italy	11	182 1.2×	130 1.2×	26 0.4×	63 1.0×	46 0.8×	29	251
Karen L. Bride United States	4	97 0.6×	29 0.3×	39 0.6×	105 1.6×	34 0.6×	7	234
Michelina Santopietro Italy	9	178 1.1×	155 1.4×	59 0.9×	22 0.3×	23 0.4×	37	234
Liwei Fang China	11	244 1.6×	147 1.3×	44 0.7×	54 0.8×	28 0.5×	31	329
Martine Klausmann Germany	7	137 0.9×	49 0.4×	56 0.8×	109 1.7×	80 1.5×	19	269

Countries citing papers authored by Anna Lübking

Since Specialization

Citations

This map shows the geographic impact of Anna Lübking's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Lübking with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Lübking more than expected).

Fields of papers citing papers by Anna Lübking

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Lübking. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Lübking. The network helps show where Anna Lübking may publish in the future.

Co-authorship network of co-authors of Anna Lübking

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Lübking. A scholar is included among the top collaborators of Anna Lübking based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Lübking. Anna Lübking is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Richter, Johan, Anna Lübking, Stina Söderlund, et al.. (2021). Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. Leukemia. 35(8). 2416–2418. 16 indexed citations

Sandin, Fredrik, Torsten Dahlén, Anna Lübking, et al.. (2021). Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry. British Journal of Haematology. 193(5). 915–921. 10 indexed citations

Söderlund, Stina, Jesper Stentoft, Johan Richter, et al.. (2021). Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study. European Journal Of Haematology. 107(6). 617–623. 5 indexed citations

Karlsson, Karin, et al.. (2020). Introducing patient‐reported outcome in the acute leukemia quality registries in Sweden. European Journal Of Haematology. 104(6). 571–580. 7 indexed citations

Lübking, Anna, Arta Dreimane, Fredrik Sandin, et al.. (2019). Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplantation. 54(11). 1764–1774. 25 indexed citations

Karlsson, Karin, Lucia Ahlberg, Hege Garelius, et al.. (2019). Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry. European Journal Of Haematology. 103(2). 88–98. 23 indexed citations

Hjorth‐Hansen, Henrik, Jesper Stentoft, Johan Richter, et al.. (2016). Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30(9). 1853–1860. 49 indexed citations

Söderlund, Stina, Torsten Dahlén, Fredrik Sandin, et al.. (2016). Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. European Journal Of Haematology. 98(1). 57–66. 7 indexed citations

Lübking, Anna, Sebastian Vosberg, Nikola P. Konstandin, et al.. (2015). Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation. Leukemia Research Reports. 4(2). 72–75. 11 indexed citations

10.

Hjorth‐Hansen, Henrik, Jesper Stentoft, Johan Richter, et al.. (2015). Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients. Blood. 126(23). 477–477. 8 indexed citations

11.

Kreil, Sebastian, Lionel Adès, Martin Bommer, et al.. (2015). Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes. Blood. 126(23). 2812–2812. 18 indexed citations

12.

Jensen, Christina T., Shabnam Kharazi, Charlotta Böiers, et al.. (2008). FLT3 ligand and not TSLP is the key regulator of IL-7–independent B-1 and B-2 B lymphopoiesis. Blood. 112(6). 2297–2304. 43 indexed citations

13.

Jensen, Christina T., Charlotta Böiers, Shabnam Kharazi, et al.. (2007). Permissive roles of hematopoietin and cytokine tyrosine kinase receptors in early T-cell development. Blood. 111(4). 2083–2090. 13 indexed citations

14.

Kasper, Christoph, et al.. (2004). Interferon alpha (IFN) treatment of bone marrow stroma inhibits haematopoesis. Leukemia Research. 28(11). 1217–1220. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact